Effect of dienogest-containing oral contraceptives on lipid metabolism

Inka Wiegratz, I Wiegratz, J H Lee, E Kutschera, Hilary Bauer, H H Bauer, Christian Hayn, C von Hayn, C. Moore, Uwe Mellinger, U Mellinger, U H Winkler, Ulrich Winkler, W Gross, Gross Wl, H. Kühl, H Kuhl
Contraception · 2002 · vol. 65(3) , pp. 223–229 · doi:10.1016/s0010-7824(01)00310-9 · PMID:11929644 · W1972262013
RCT OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated the impact of dienogest-containing oral contraceptives on lipid metabolism in women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a double-blind, controlled, randomized, four-arm, bicentric clinical study, the effect of four oral contraceptives (OCs) on lipid metabolism was investigated. Four groups composed of 25 volunteers each (mean age 26.1 +/- 4.5 years; body mass index 21.9 +/- 2.8 kg/m(2)) were treated for six cycles with monophasic combinations containing 21 tablets with either 30 microg ethinyl estradiol (EE) + 2 mg dienogest (DNG) (30 EE/DNG), 20 microg EE + 2 mg DNG (20 EE/DNG), 10 microg EE + 2 mg estradiol valerate (EV) + 2 mg DNG (EE/EV/DNG), or 20 microg EE + 100 microg levonorgestrel (LNG; EE/LNG). The study was completed by 91 women. Blood samples were taken by venipuncture after at least 12 h fasting on Days 21-26 of the control cycle and Days 18-21 of the first, third, and sixth treatment cycle. There were clear differences between the effects of EE/LNG and the formulations containing estrogens and DNG. Although EE/LNG did not change the triglycerides levels, a significant increase was observed during treatment with the DNG-containing preparations. Although EE/LNG significantly reduced HDL-CH and HDL(2)-CH, there was a nonsignificant increase with the DNG-containing OCs. No change was observed in the levels of HDL(3)-CH. A significant rise in apolipoprotein A1 occurred during intake with the three DNG-containing formulations, but not with EE/LNG. In contrast to the women treated with combinations of estrogens and DNG, apolipoprotein B rose significantly in the women in the EE/LNG group. Lipoprotein (a) was significantly reduced by 30 EE/DNG and EE/LNG and remained unaltered with 20 EE/DNG and EE/EV/DNG. Altogether, the changes in lipid metabolism caused by the DNG-containing formulations appeared to be more favorable than those observed with EE/LNG. In OCs with DNG, the EE dose does not seem to play a major role with respect to the effect on lipids.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral, Combined Estradiol Lipids Nandrolone Nandrolone Adolescent Adult Contraceptives, Oral, Combined Double-Blind Method Estradiol Estradiol Estrogens, Conjugated (USP) Estrogens, Conjugated (USP) Ethinyl Estradiol Ethinyl Estradiol Female Humans Levonorgestrel Levonorgestrel Lipids

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (39)

Cited by (15)

Source provenance

openalex
last seen: 2026-05-11T06:20:36.346967+00:00
pubmed
last seen: 2026-10-08T21:00:24.492322+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK